Golden Grail Technology's AccurateVenture and Novus MedPlan Execute Strategic Partnership Agreement

AccurateVenture's Hemp Products Now Covered Nationwide Under Novus MedPlan; Novus MedPlan to be Offered to AccurateVenture Customers

WESTON, FL / ACCESSWIRE / March 16, 2017 / Golden Grail Technology GOGY ("Golden Grail" or the "Company"), a technology and software solutions provider to companies with unique value propositions operating in mass market consumer sectors, today announced a strategic partnership with insurance provider Novus MedPlan NDEV. Marketing and processing under the Strategic Partnership Agreement is targeted to start in early April 2017.

Golden Grail's wholly-owned subsidiary AccurateVenture is proud to announce it has executed a Strategic Partnership Agreement with Novus MedPlan. Novus will now cover the bioRenovate® Pharmaceutical Grade Hemp Cannabidiol products and the consumer Miracle Brand CBD products, under its Novus MedPlan Insurance Policy.

Novus MedPlan is the nation's first health plan that focuses on reducing your cost associated with Medical Marijuana and Hemp/CBD (Cannabidiol). This revolutionary service fills the gaps where your insurance policies do not provide coverage or discounts. Novus offers highly affordable plans to people with and without current health insurance. Novus CEO, Frank Labrozzi, stated, "It's exciting to be working with an industry leader with a significant customer base in the cannabis space. There is no doubt AccurateVenture will help to make Novus MedPlan an even more recognized name and allow us to offer it to a much broader client base."

The Agreement calls for AccurateVenture to offer its customers an opportunity to purchase the Novus MedPlan insurance right on the checkout page, while purchasing any of AccurateVenture's Cannabidiol products, simply by checking a box.

"Novus is clearly out in front of the insurance industry in the cannabis space," stated, AccurateVenture CEO, Bill Fisher. "When I started strategizing back in 2014, I knew one of the most challenging obstacles would be the cost of true pharma-grade product for people without insurance. Novus is an answered prayer for those who use hemp products for health and wellness on a daily basis, and we are excited to get started."

Although the bioRenovate and Miracle Brands are now officially covered by Novus, AccurateVenture is currently in the web-engineering phase of implementing the sales funnel to adopt the new Novus sign-ups into its daily process. The web program should launch by early April 2017.

About Novus

Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as, health, property & casualty, life, accident and fixed annuities.

Novus medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is competed the transaction is solely between the state-licensed dispensary and the registered patient.

The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly. Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis related products, we may be harmed by a change in enforcement by federal or state governments.

• For more information, please visit: http://www.getnovusnow.com
• For NDEV 3rd Quarter Financial Filing: http://bit.ly/2hNHQSg
• Learn How Insurance Companies Are Evaluated: http://bit.ly/2ddIYva

About Golden Grail Technology Corp.

Golden Grail Technology Corp. (GOGY) is a technology and software solutions provider to companies with unique value propositions operating in mass market consumer sectors such as jewelry, health and personal care, beauty, electronics, pet and animal supplies, sports and games. Golden Grail's mission is to utilize their network of industry experts, who specialize in targeting areas of business that can be accelerated with technology, in order to give small companies an opportunity to compete with industry giants.

For more information, please visit: http://goldengrailtechnology.com
And: http://accurateventure.com

Forward-Looking Statements

Except for the historical and present factual information contained in this press release, the matters discussed in this press release, including statements identified by words such as "will," "expected," "plans," and similar expressions are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements, including the factors described in filings with OTC Markets, including but not limited to discussion under the caption "Risk Factors." Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's judgment solely as of the date hereof.

Contact Information

Hayden IR
(917) 658-7878
hart@haydenir.com

SOURCE: Golden Grail Technology Corp.